Listed

Prime Medicine, Inc.

PRMENasdaqCIK 1894562HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$838.0k, Q4 FY2025
Operating income−$43.3m, Q2 FY2026
Net income−$42.1m, Q2 FY2026
Prime Medicine, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0001628280-25-008884. Derived: 12-month figure less the 9-month figure.Report this figure0.6Revenue, Q1 FY2024, three months to 2024-03-31$591.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure0.2Revenue, Q3 FY2024, three months to 2024-09-30$209.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure2.2Revenue, Q4 FY2024, three months to 2024-12-31$2.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure1.5Revenue, Q1 FY2025, three months to 2025-03-31$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure1.1Revenue, Q2 FY2025, three months to 2025-06-30$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure1.2Revenue, Q3 FY2025, three months to 2025-09-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure0.8Revenue, Q4 FY2025, three months to 2025-12-31$838.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Research and development$m41.0Research and development, Q3 FY2023, three months to 2023-09-30$41.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure41.5Research and development, Q4 FY2023, three months to 2023-12-31$41.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-28, accession 0001628280-25-008884. Derived: 12-month figure less the 9-month figure.Report this figure37.8Research and development, Q1 FY2024, three months to 2024-03-31$37.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure43.1Research and development, Q2 FY2024, three months to 2024-06-30$43.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure40.3Research and development, Q3 FY2024, three months to 2024-09-30$40.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure34.1Research and development, Q4 FY2024, three months to 2024-12-31$34.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure40.6Research and development, Q1 FY2025, three months to 2025-03-31$40.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure41.4Research and development, Q2 FY2025, three months to 2025-06-30$41.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure44.0Research and development, Q3 FY2025, three months to 2025-09-30$44.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure34.7Research and development, Q4 FY2025, three months to 2025-12-31$34.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure34.1Research and development, Q1 FY2026, three months to 2026-03-31$34.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure33.4Research and development, Q2 FY2026, three months to 2026-06-30$33.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Operating income$m(51.5)Operating income, Q3 FY2023, three months to 2023-09-30−$51.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure(68.0)Operating income, Q4 FY2023, three months to 2023-12-31−$68.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-28, accession 0001628280-25-008884. Derived: 12-month figure less the 9-month figure.Report this figure(48.3)Operating income, Q1 FY2024, three months to 2024-03-31−$48.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure(55.7)Operating income, Q2 FY2024, three months to 2024-06-30−$55.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure(54.2)Operating income, Q3 FY2024, three months to 2024-09-30−$54.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(44.2)Operating income, Q4 FY2024, three months to 2024-12-31−$44.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(52.4)Operating income, Q1 FY2025, three months to 2025-03-31−$52.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(53.4)Operating income, Q2 FY2025, three months to 2025-06-30−$53.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure(54.0)Operating income, Q3 FY2025, three months to 2025-09-30−$54.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(48.6)Operating income, Q4 FY2025, three months to 2025-12-31−$48.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(50.7)Operating income, Q1 FY2026, three months to 2026-03-31−$50.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(43.3)Operating income, Q2 FY2026, three months to 2026-06-30−$43.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Income tax$m(0.1)Income tax, Q3 FY2023, three months to 2023-09-30−$108.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-02-28, accession 0001628280-25-008884. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2024, three months to 2024-03-31$134.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure(0.1)Income tax, Q2 FY2024, three months to 2024-06-30−$134.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figurenot reportednot reportednot reportednot reported
Net income$m(50.7)Net income, Q3 FY2023, three months to 2023-09-30−$50.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure(65.6)Net income, Q4 FY2023, three months to 2023-12-31−$65.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0001628280-25-008884. Derived: 12-month figure less the 9-month figure.Report this figure(45.8)Net income, Q1 FY2024, three months to 2024-03-31−$45.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(55.3)Net income, Q2 FY2024, three months to 2024-06-30−$55.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(52.5)Net income, Q3 FY2024, three months to 2024-09-30−$52.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(42.3)Net income, Q4 FY2024, three months to 2024-12-31−$42.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(51.9)Net income, Q1 FY2025, three months to 2025-03-31−$51.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure(52.6)Net income, Q2 FY2025, three months to 2025-06-30−$52.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure(50.6)Net income, Q3 FY2025, three months to 2025-09-30−$50.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure(46.1)Net income, Q4 FY2025, three months to 2025-12-31−$46.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(49.1)Net income, Q1 FY2026, three months to 2026-03-31−$49.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure(42.1)Net income, Q2 FY2026, three months to 2026-06-30−$42.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Diluted EPS$ per share(0.55)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figurenot reported(0.44)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure(0.46)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure(0.44)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figurenot reported(0.40)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(0.41)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure(0.32)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figurenot reported(0.28)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(0.24)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Basic EPS$ per share(0.55)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figurenot reported(0.44)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure(0.46)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure(0.44)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figurenot reported(0.40)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.40 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(0.41)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure(0.32)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.32 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figurenot reported(0.28)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(0.24)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure

Balance sheet

Cash and equivalents$47.5m, Q2 FY2026
Shareholders' equity$39.8m, Q2 FY2026
Prime Medicine, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m44.0Cash and equivalents, Q3 FY2023, at 2023-09-30$44.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure41.6Cash and equivalents, FY2023, at 2023-12-31$41.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-28, accession 0001628280-25-008884.Report this figure94.2Cash and equivalents, Q1 FY2024, at 2024-03-31$94.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure55.6Cash and equivalents, Q2 FY2024, at 2024-06-30$55.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure118Cash and equivalents, Q3 FY2024, at 2024-09-30$118.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure182Cash and equivalents, FY2024, at 2024-12-31$182.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure91.9Cash and equivalents, Q1 FY2025, at 2025-03-31$91.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure53.8Cash and equivalents, Q2 FY2025, at 2025-06-30$53.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure71.4Cash and equivalents, Q3 FY2025, at 2025-09-30$71.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure63.0Cash and equivalents, FY2025, at 2025-12-31$63.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure64.1Cash and equivalents, Q1 FY2026, at 2026-03-31$64.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure47.5Cash and equivalents, Q2 FY2026, at 2026-06-30$47.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Current assets$m185Current assets, Q3 FY2023, at 2023-09-30$184.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-03, accession 0001628280-23-036777.Report this figure143Current assets, FY2023, at 2023-12-31$143.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-28, accession 0001628280-25-008884.Report this figure218Current assets, Q1 FY2024, at 2024-03-31$217.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-10, accession 0001628280-24-022473.Report this figure171Current assets, Q2 FY2024, at 2024-06-30$170.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-035893.Report this figure246Current assets, Q3 FY2024, at 2024-09-30$246.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure212Current assets, FY2024, at 2024-12-31$211.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure164Current assets, Q1 FY2025, at 2025-03-31$163.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure121Current assets, Q2 FY2025, at 2025-06-30$121.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure231Current assets, Q3 FY2025, at 2025-09-30$231.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure181Current assets, FY2025, at 2025-12-31$181.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure138Current assets, Q1 FY2026, at 2026-03-31$137.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure96.8Current assets, Q2 FY2026, at 2026-06-30$96.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Total assets$m239Total assets, Q3 FY2023, at 2023-09-30$239.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-03, accession 0001628280-23-036777.Report this figure194Total assets, FY2023, at 2023-12-31$193.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-28, accession 0001628280-25-008884.Report this figure311Total assets, Q1 FY2024, at 2024-03-31$311.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-10, accession 0001628280-24-022473.Report this figure260Total assets, Q2 FY2024, at 2024-06-30$259.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001628280-24-035893.Report this figure333Total assets, Q3 FY2024, at 2024-09-30$332.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure298Total assets, FY2024, at 2024-12-31$297.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure328Total assets, Q1 FY2025, at 2025-03-31$328.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure279Total assets, Q2 FY2025, at 2025-06-30$279.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure385Total assets, Q3 FY2025, at 2025-09-30$385.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure343Total assets, FY2025, at 2025-12-31$342.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure295Total assets, Q1 FY2026, at 2026-03-31$294.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure249Total assets, Q2 FY2026, at 2026-06-30$249.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Current liabilities$m39.4Current liabilities, Q3 FY2023, at 2023-09-30$39.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-03, accession 0001628280-23-036777.Report this figure56.4Current liabilities, FY2023, at 2023-12-31$56.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-28, accession 0001628280-25-008884.Report this figure24.4Current liabilities, Q1 FY2024, at 2024-03-31$24.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-10, accession 0001628280-24-022473.Report this figure20.7Current liabilities, Q2 FY2024, at 2024-06-30$20.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-035893.Report this figure37.9Current liabilities, Q3 FY2024, at 2024-09-30$37.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure38.0Current liabilities, FY2024, at 2024-12-31$38.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure34.3Current liabilities, Q1 FY2025, at 2025-03-31$34.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure34.1Current liabilities, Q2 FY2025, at 2025-06-30$34.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure35.0Current liabilities, Q3 FY2025, at 2025-09-30$35.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure37.4Current liabilities, FY2025, at 2025-12-31$37.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure36.3Current liabilities, Q1 FY2026, at 2026-03-31$36.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure31.7Current liabilities, Q2 FY2026, at 2026-06-30$31.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Total liabilities$m45.2Total liabilities, Q3 FY2023, at 2023-09-30$45.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-03, accession 0001628280-23-036777.Report this figure60.8Total liabilities, FY2023, at 2023-12-31$60.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-28, accession 0001628280-25-008884.Report this figure67.6Total liabilities, Q1 FY2024, at 2024-03-31$67.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-10, accession 0001628280-24-022473.Report this figure63.1Total liabilities, Q2 FY2024, at 2024-06-30$63.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001628280-24-035893.Report this figure143Total liabilities, Q3 FY2024, at 2024-09-30$143.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure144Total liabilities, FY2024, at 2024-12-31$144.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure221Total liabilities, Q1 FY2025, at 2025-03-31$221.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure218Total liabilities, Q2 FY2025, at 2025-06-30$218.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure223Total liabilities, Q3 FY2025, at 2025-09-30$223.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure222Total liabilities, FY2025, at 2025-12-31$221.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure218Total liabilities, Q1 FY2026, at 2026-03-31$218.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure209Total liabilities, Q2 FY2026, at 2026-06-30$209.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure
Shareholders' equity$m194Shareholders' equity, Q3 FY2023, at 2023-09-30$194.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure133Shareholders' equity, FY2023, at 2023-12-31$133.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-03, accession 0001628280-26-013569.Report this figure244Shareholders' equity, Q1 FY2024, at 2024-03-31$243.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure197Shareholders' equity, Q2 FY2024, at 2024-06-30$196.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure190Shareholders' equity, Q3 FY2024, at 2024-09-30$189.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure153Shareholders' equity, FY2024, at 2024-12-31$153.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure107Shareholders' equity, Q1 FY2025, at 2025-03-31$106.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure60.9Shareholders' equity, Q2 FY2025, at 2025-06-30$60.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure162Shareholders' equity, Q3 FY2025, at 2025-09-30$161.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure121Shareholders' equity, FY2025, at 2025-12-31$120.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure76.7Shareholders' equity, Q1 FY2026, at 2026-03-31$76.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure39.8Shareholders' equity, Q2 FY2026, at 2026-06-30$39.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure

Cash flow

Operating cash flow−$41.0m, Q2 FY2026
Capital expenditure$46.0k, Q2 FY2026
Prime Medicine, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(39.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$39.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001628280-24-047130. Derived: 9-month figure less the 6-month figure.Report this figure(43.9)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$43.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-28, accession 0001628280-25-008884. Derived: 12-month figure less the 9-month figure.Report this figure(67.7)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$67.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure(45.5)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$45.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001628280-25-038619. Derived: 6-month figure less the 3-month figure.Report this figure(25.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$25.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001628280-25-050422. Derived: 9-month figure less the 6-month figure.Report this figure16.2Operating cash flow, Q4 FY2024, three months to 2024-12-31$16.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(48.9)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$48.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(41.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$41.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Report this figure(35.0)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$35.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-07, accession 0001628280-25-050422. Derived: 9-month figure less the 6-month figure.Report this figure(37.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$37.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure(42.7)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$42.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure(41.0)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$41.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m2.9Capital expenditure, Q3 FY2023, three months to 2023-09-30$2.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001628280-24-047130. Derived: 9-month figure less the 6-month figure.Report this figure1.8Capital expenditure, Q4 FY2023, three months to 2023-12-31$1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-28, accession 0001628280-25-008884. Derived: 12-month figure less the 9-month figure.Report this figure2.3Capital expenditure, Q1 FY2024, three months to 2024-03-31$2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure1.9Capital expenditure, Q2 FY2024, three months to 2024-06-30$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001628280-25-038619. Derived: 6-month figure less the 3-month figure.Report this figure1.3Capital expenditure, Q3 FY2024, three months to 2024-09-30$1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001628280-25-050422. Derived: 9-month figure less the 6-month figure.Report this figure1.8Capital expenditure, Q4 FY2024, three months to 2024-12-31$1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure2.4Capital expenditure, Q1 FY2025, three months to 2025-03-31$2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure1.6Capital expenditure, Q2 FY2025, three months to 2025-06-30$1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Report this figure0.2Capital expenditure, Q3 FY2025, three months to 2025-09-30$247.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-07, accession 0001628280-25-050422. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2025, three months to 2025-12-31$290.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001628280-26-013569. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2026, three months to 2026-03-31$214.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$46.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053883. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)177.22m, Q2 FY2026
Prime Medicine, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares22.2Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3022,226,301 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-03, accession 0001628280-23-036777.Report this figure89.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3189,064,895 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-10, accession 0001628280-24-022473.Report this figure90.5Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3090,467,298 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001628280-24-035893.Report this figure91.8Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3091,846,835 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001628280-24-047130.Report this figure104Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31104,466,178 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001628280-25-023486.Report this figure119Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30119,188,866 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001628280-25-038619.Report this figure120Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30119,764,270 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure131Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31130,884,490 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure129Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30129,185,918 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure161Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30160,503,183 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-07, accession 0001628280-25-050422.Report this figure177Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31177,096,225 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001628280-26-031726.Report this figure177Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30177,224,892 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure

Shares outstanding: 181.38mShares outstanding, period not labelled, at 2026-07-31181,376,856 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001628280-26-053883.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.